Trials / Completed
CompletedNCT04025957
A Study of SHR-1501 in Patients With Advanced Tumors
A Phase I Study on Tolerance, Safety and Pharmacokinetics of SHR-1501 in Patients With Advanced Malignancies.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in patients with advanced malignancies .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1501 | Administered subcutaneously |
Timeline
- Start date
- 2019-10-30
- Primary completion
- 2022-07-31
- Completion
- 2022-07-31
- First posted
- 2019-07-19
- Last updated
- 2023-09-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04025957. Inclusion in this directory is not an endorsement.